[1]杨 帆,李 娟,何 昉,等.利胆退黄汤治疗非酒精性脂肪性肝病疗效及对患者肝功能、糖脂代谢和血清脂肪因子的影响[J].陕西中医,2023,(10):1404-1407.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
　YANG Fan,LI Juan,HE Fang,et al.Lidan Tuihuang decoction on liver function,glycolipid metabolism,and serum adipose factors in the treatment of non alcoholic fatty liver disease[J].,2023,(10):1404-1407.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
点击复制

利胆退黄汤治疗非酒精性脂肪性肝病疗效及对患者肝功能、糖脂代谢和血清脂肪因子的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年10期
页码:
1404-1407
栏目:
临床研究
出版日期:
2023-10-05

文章信息/Info

Title:
Lidan Tuihuang decoction on liver function,glycolipid metabolism,and serum adipose factors in the treatment of non alcoholic fatty liver disease
作者:
杨 帆; 李 娟; 何 昉; 成 功
(甘肃省人民医院消化科,甘肃 兰州 730099)
Author(s):
YANG Fan; LI Juan; HE Fang; CHENG Gong
(Department of Gastroenterology,Gansu Provincial Hospital,Lanzhou 730099,China)
关键词:
非酒精性脂肪性肝病;  利胆退黄汤;  肝功能;  糖脂代谢;  脂肪因子;  瘦素
Keywords:
Non alcoholic fatty liver disease;  Lidan Tuihuang decoction;  Liver function;  Glycolipid metabolism;  Adipokines;  Leptin
分类号:
R 575.5
DOI:
DOI:10.3969/j.issn.1000-7369.2023.10.015
文献标志码:
A
摘要:
目的:探究利胆退黄汤治疗非酒精性脂肪性肝病及对患者肝功能、糖脂代谢和血清脂肪因子的影响。方法:将100例非酒精性脂肪性肝病患者随机分为研究组和对照组,每组各50例,对照组餐后口服多烯磷酸酯胆碱胶囊,研究组在对照组基础上联合利胆退黄汤治疗。治疗12周后,比较两组的疗效、中医症候、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、空腹血糖(FPG)、空腹胰岛素(FINS)、总胆固醇(TC)、甘油三酯(TG)、低/高密度脂蛋白胆固醇(LDL-C/HDL-C)、视黄醇结合蛋白-4(RBP-4)、固醇调节元件结合蛋白-1C(SREBP-1C)、瘦素、脂联素及不良反应。结果:治疗后,两组患者的主症评分、次症评分、ALT、AST、FPG、FINS、TC、TG、LDL-C、RBP-4、SREBP-1C、瘦素较治疗前均降低,研究组低于对照组(P<0.05); 两组患者的HDL-C、脂联素较治疗前均升高,研究组高于对照组(P<0.05)。研究组患者的治疗有效率高于对照组(P<0.05)。两组均未出现严重不良反应。结论:利胆退黄汤治疗非酒精性脂肪性肝病,有利于调节患者的糖脂代谢功能,改善肝功能,提升疗效。
Abstract:
Objective:To explore the effects of Lidan Tuihuang decoction on liver function,glucose and lipid metabolism,and serum adipose factors in the treatment of non-alcoholic fatty liver disease.Methods:A total of 100 patients with non-alcoholic fatty liver disease were randomly divided into a study group and a control group,with 50 cases in each group.The control group received oral administration of polyene phosphate choline capsules after meals,while the study group received treatment with Lidan Tuihuang decoction on the basis of the control group.After 12 weeks of treatment,the efficacy,TCM syndromes,alanine aminotransferase(ALT),aspartate aminotransferase(AST),fasting blood glucose(FPG),fasting insulin(FINS),total cholesterol(TC),triglyceride(TG),low/high-density lipoprotein cholesterol(LDL-C/HDL-C),retinol binding protein-4(RBP-4),sterol regulatory element binding protein-1C(SREBP-1C),Leptin,adiponectin,and adverse reactions.Results:After treatment,the main syndrome score,secondary syndrome score,ALT,AST,FPG,FINS,TC,TG,LDL-C,RBP-4,SREBP-1C,and leptin of the two groups of patients decreased compared to before treatment,and the study group was lower than the control group(P<0.05).The levels of HDL-C and adiponectin in both groups of patients increased compared to before treatment,and the study group was higher than the control group(P<0.05).The treatment effectiveness rate of the study group patients was higher than that of the control group(P<0.05).Both groups did not experience serious adverse reactions.Conclusion:Lidan Tuihuang decoction is beneficial for regulating the glucose and lipid metabolism function of patients with non-alcoholic fatty liver disease,improving liver function,and enhancing therapeutic effect.

参考文献/References:

[1] 林先佳,王小锋,张媛媛,等.基于网络药理学和分子对接探讨肝脂平治疗非酒精性脂肪性肝病作用机制[J].陕西中医,2023,44(4):524-529.
[2] Fianchi F,Liguori A,Gasbarrini A,et al.Nonalcoholic fatty liver disease(NAFLD)as model of gut-liver axis interaction:From pathophysiology to potential target of treatment for personalized therapy[J].Int J Mol Sci,2021,22(12):6485.
[3] 唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,43(10):1359-1363,1368.
[4] 张欣欣.降脂保肝汤对非酒精性脂肪性肝病的作用观察[J].中国中医药科技,2022,29(4):671-673.
[5] 顾晓琦,钱程亮,曹 琳,等.加味利胆退黄汤联合利巴韦林、干扰素α治疗湿热蕴结型慢性丙型肝炎临床观察[J].辽宁中医杂志,2022,49(9):112-115.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
[7] 国家中医药管理局医政司.中医病症诊断疗效标准[M].南京:南京大学出版社,2017:229.
[8] 王敏娟,王敏雯,郭 艳,等.膳食炎症指数与老年人非酒精性脂肪性肝病关系研究[J].陕西医学杂志,2020,49(12):1589-1592.
[9] 李 婧,李小凤,闫 妮,等.胰岛素抵抗代谢评分在中老年人群非酒精性脂肪性肝病筛查中的价值研究[J].陕西医学杂志,2023,52(6):688-692.
[10] Mauro S,Scamporrino A,Filippello A,et al.Clinical and molecular biomarkers for diagnosis and staging of NAFLD[J].Int J Mol Sci,2021,22(21):11905.
[11] Cotter TG,Rinella M.Nonalcoholic fatty liver disease 2020:The state of the disease[J].Gastroenterology,2020,158(7):1851-1864.
[12] 丁佳璐,方晨晔.基于《金匮要略》探讨经方在非酒精性脂肪性肝病治疗中的应用[J].江苏中医药,2021,53(2):21-23.
[13] 王 敏,唐金模,梁惠卿,等.非酒精性脂肪性肝病患者中医证型与血清铁蛋白、转铁蛋白及CAP相关性[J].中西医结合肝病杂志,2022,32(9):790-793.
[14] 王争艳,李正军.大黄利胆片对非酒精性脂肪性肝病湿热蕴结证患者血清IL-1 RA、IL-1β、IL-18水平和肠道菌群的影响[J].南京中医药大学学报,2020,36(5):762-766.
[15] 高改娅,李 莎,薛敬东,等.非酒精性脂肪性肝病中医证型及证素研究[J].临床肝胆病杂志,2021,37(1):89-93.
[16] 陈小兰,朱 琪.中医在非酒精性脂肪性肝病治疗中的运用探讨[J].中国医药导刊,2020,22(9):604-606.
[17] 苟小军,刘丽萍,马诗瑜,等.非酒精性脂肪性肝病肝胆湿热证患者尿液代谢组学研究[J].中华中医药杂志,2020,35(8):3846-3853.
[18] 庄鸿莉,梁惠卿,林 立,等.湿热质非酒精性脂肪性肝病患者的证素分布规律及与肝组织学的相关性[J].中华中医药杂志,2021,36(4):2286-2289.
[19] 刘玉萍,邱小玉,刘 烨,等.茵陈的药理作用研究进展[J].中草药,2019,50(9):2235-2241.
[20] 高云霄,李 泽,杨 柳,等.基于网络药理学和分子对接探讨柴胡-大黄药对防治胆石症的作用机制[J].世界中医药,2022,17(4):447-454.

相似文献/References:

[1]黄 进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,(2):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
　HUANG Jin,LU Xueping.Analysis of treatment of nonalcoholic fatty liver disease from spleen[J].,2021,(10):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
[2]唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,(10):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
　TANG Yinghui,YE Miaoqing,HE Jinyu,et al.Huazhi Fugan granule alleviates Kupffer cell inflammation by inhibiting TLR4/NF-κB/NLRP3 and improves nonalcoholic fatty liver disease[J].,2022,(10):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
[3]林先佳,王小锋,张媛媛,等.基于网络药理学和分子对接探讨肝脂平治疗非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(4):524.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.027]
[4]赵梦溪,罗 斌,吕建瑞,等.隐丹参酮调节AMPK/Nrf2信号通路治疗小鼠非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(8):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
　ZHAO Mengxi,LUO Bin,LYU Jianrui,et al.Mechanism of cryptotanshinone regulates AMPK/Nrf2 signaling pathway to treat nonalcoholic fatty liver disease in mouse[J].,2023,(10):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
[5]李秀秀,张玉佩,许春玲,等.基于胆汁酸-肠道菌群对话机制探讨非酒精性脂肪性肝病肝郁脾虚病机特点[J].陕西中医,2024,(6):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
　LI Xiuxiu,ZHANG Yupei,XU Chunling,et al.Exploration of the pathogenic characteristics of non-alcoholic fatty liver disease with liver depression and spleen deficiency based on the bile acid-gut microbiota dialogue mechanism[J].,2024,(10):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
[6]罗 艺,周晓玲,刘 琳,等.非酒精性脂肪性肝病中医治疗研究进展[J].陕西中医,2024,(6):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]
　LUO Yi,ZHOU Xiaoling,LIU Lin,et al.Research progress on traditional Chinese medicine treatment of nonalcoholic fatty liver disease[J].,2024,(10):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]

备注/Memo

备注/Memo:
基金项目:甘肃省自然科学基金资助项目(21JR7RA629)
更新日期/Last Update: 2023-10-09